ASX COVID-19 test shares are in the green today amid a federal government announcement. This morning Treasurer Josh Frydenberg outlined the government’s plan to make the tests tax deductible.
ASX-listed companies that manufacture COVID-19 tests include Atomo Diagnostics Ltd (ASX: AT1), Lumos Diagnostics Holdings Ltd (ASX: LDX) and AnteoTech Ltd (ASX: ADO.
Atomo’s share price is currently climbing 1.19% today, while Lumos is in the green 2.49 and Anteotech is jumping 6.98%.
Let’s take a look at the news that could be giving these shares a bump today.
Tax deductible COVID-19 tests
COVID-19 tests for people who need them for work will be tax deductible from this year, the Financial Review reported.
Sonic Healthcare Limited (ASX: SHL) and Healius Ltd (ASX: HLS) process COVID-19 tests in Australia. Sonic has conducted millions of PCR tests, while Healius is processing 40,000 COVID-19 tests every day.
Treasurer Frydenberg will discuss the tax deduction policy in a speech to the Australian Industry Group today. In a copy of the speech, reported by the SBS, he states:
Today, I’m announcing that we will ensure that COVID-19 testing expenses are tax deductible for testing taken to attend a place of work, giving businesses and individuals more clarity and assurance.
We will also ensure that fringe benefits tax will not be incurred by employers where COVID-19 tests are provided to employees for this purpose.
The Lumos share price surged 5% last week on news the Victorian Government intends to support local manufacturing of its RAT tests.
Atomo secured up to 20 million COVID-19 rapid antigen tests for Australia and New Zealand in 2022, my Foolish colleague Aaron reported in January.
Anteotech is still awaiting Therapeutic Goods Administration (TGA) approval for use of its COVID-19 rapid antigen test in Australia.
Ellume is another Australian company working on TGA approval to sell its RATs in Australia. However, it is not listed on the ASX.
Share price recap
Some COVID-19 test shares have benefitted from the pandemic, making major gains in the past 52 weeks.
In the past year, Anteotech has rocketed 27%, while Sonic has surged 9% and Healius has gained 8%.
However, that’s not true across the board. The Atomo share price has slumped 27% while the Lumos share price is down 17%.
In contrast, the S&P/ASX 200 Index (ASX: XJO) has returned more than 3.4% in the past year.
The post Why are ASX COVID test shares climbing today? appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of January 12th 2022
More reading
- 2 ASX shares every dividend investor needs to know about
- The Lumos Diagnostics (ASX:LDX) share price is soaring another 8% today. Here’s why
- Why the Lumos Diagnostics (ASX:LDX) share price is up 15% today
- 2 great value ASX dividend shares that brokers love
- AnteoTech (ASX:AD) share price surges 15% as COVID-19 RAT race continues
The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/p9YTrUZ
Leave a Reply